Novavax reported $-307144000 in EBIT for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Adamas Pharmaceuticals ADMS:US -5636000 3.52M
Adma Biologics ADMA:US $ -14437080 1.14M
Astrazeneca AZN:US -4000000 1.45B
AstraZeneca AZN:LN -4000000 1.45B
Biocryst Pharmaceuticals BCRX:US $ -44584000 15M
Genocea Biosciences GNCA:US $ -11716000 2.83M
Geron GERN:US $ -25674000 3.22M
GlaxoSmithKline GSK:LN 2.67B 712M
Kindred Biosciences KIN:US -8544000 622K
Mannkind MNKD:US $ -8552000 479K
Merk MRK:US $ 5352M 3083M
Minerva Neurosciences NERV:US $ -7517620 1.45M
Moderna Inc MRNA:US 3.56B 496M
Novartis NVS:US 3.48B 77M
Novavax NVAX:US $ -307144000 38.68M
Pain Therapeutics PTIE:US $ -9753000 4.62M
Peregrine Pharmaceuticals PPHM:US $ 6.93M 3.84M
Pfizer PFE:US $ 9254M 2592M
Sarepta Therapeutics SRPT:US $ -34458000 133.12M
Tg Therapeutics TGTX:US $ -85128000 7.64M